Citius Oncology (CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals (CTXR), announced it has finalized an exclusive agreement with EVERSANA, a provider of global commercialization services, to support the anticipated fourth quarter 2025 U.S. commercialization of LYMPHIR, Citius Oncology’s FDA-approved therapy for relapsed or refractory cutaneous T-cell lymphoma following at least one prior systemic therapy. Under the Master Service Agreement, EVERSANA will serve as Citius Oncology’s exclusive commercialization partner, providing an integrated suite of pre- and post-launch operations services. These services include medical information, pharmacovigilance, revenue cycle management, program management, data and analytics, and channel management. As launch preparations advance, additional commercialization services are expected to be integrated.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTOR:
- Citius Oncology’s Strategic Expansion and Market Positioning Drive Buy Rating
- Citius Oncology signs distribution agreement for Lymphir in Southern Europe
- Maxim upgrades Citius Oncology to Buy, sees its capital needs being met
- Citius Oncology upgraded to Buy from Hold at Maxim
- Citius Oncology Issues Warrants in Private Placement